Based on key findings from our cohort, we developed a novel prognostic model for 5-year DFS incorporating TIL level (≤ 10% vs. > 10%), TRAG status (mutant vs. wild-type), and clinicopathological features, including tumor size (> 2.0 cm vs. ≤ 2.0 cm), ALN status (positive vs. negative), and ER status (negative vs. positive) [Figure 4A and Supplementary Table 8]. The gene discussed is ARLN; the disease is neoplasm.